ArriVent BioPharma (AVBP) EV/EBITDA: History & Chart

ArriVent BioPharma, Inc.(AVBP)

Biotechnology · Newtown Square, PA

$13.03-15.43 (-54.22%)

Delayed quote: Oct 6, 2026, 11:25 AM EDT

About ArriVent BioPharma, Inc.

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Newtown Square, PA

77 employees

arrivent.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Zhengbin Yao

View full financials

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
ArriVent BioPharma, Inc. (AVBP)	$606.87M	N/A	N/A	N/A	N/A
Ironwood Pharmaceuticals, Inc. (IRWD)vs ›	$603.31M	3.87x	7.68x	8.80x	8.39x
AngioDynamics, Inc. (ANGO)vs ›	$612.96M	N/A	8.45x	304.75x	435.98x
Fulgent Genetics, Inc. (FLGT)vs ›	$591.58M	N/A	2.62x	44.68x	68.34x
Prime Medicine, Inc. (PRME)vs ›	$624.03M	N/A	N/A	N/A	N/A
OrthoPediatrics Corp. (KIDS)vs ›	$583.78M	N/A	N/A	N/A	N/A
Aquestive Therapeutics, Inc. (AQST)vs ›	$574.60M	N/A	42.12x	42.12x	42.12x
Climb Bio, Inc. (CLYM)vs ›	$640.77M	N/A	N/A	N/A	N/A
Aura Biosciences, Inc. (AURA)vs ›	$644.93M	N/A	N/A	N/A	N/A
CytomX Therapeutics, Inc. (CTMX)vs ›	$568.81M	N/A	13.55x	10.69x	10.69x

NAME

MARKET CAP

EV/EBITDA RATIO

TTM

ArriVent BioPharma, Inc. (AVBP)

$606.87M

N/A

Ironwood Pharmaceuticals, Inc. (IRWD)vs ›

$603.31M

3.87x

7.68x

8.80x